CervoMed Inc (CRVO) News

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Form 8-K - Current report

CervoMed Announces Key Senior Leadership Appointments

BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on...

CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

- Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in...

CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup

The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life...

CervoMed to Participate in Upcoming Investor Conferences

BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on...

Form 8-K - Current report

CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)

Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial...

Form 8-K - Current report

CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference

Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data...

Form 8-K - Current report

CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)

• On track to report topline data from the Phase 2b trial in December 2024 • Neflamapimod has the potential to...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness